Laforin, a protein with many faces: Glucan phosphatase, adapter protein, et al.ii

FEBS Journal

Volumn 280, Issue 2, 2013, Pages 525-537

  Gentry, Matthew S ^a   Romá Mateo, Carlos ^b   Sanz, Pascual ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

autophagy; endoplasmic reticulum stress; glucan phosphatase; glycogen; Lafora bodies; Lafora disease; laforin; malin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBOHYDRATE; CYSTEINE; DUAL SPECIFICITY PHOSPHATASE; GENTAMICIN; GLUCAN PHOSPHATASE; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LAFORIN PROTEIN; MALIN ENZYME; RECOMBINANT PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBIOTIC THERAPY; ARTICLE; AUTOPHAGY; BIOACCUMULATION; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL ACTIVITY; CELL INCLUSION; CHEMICAL ANALYSIS; CLINICAL FEATURE; COMPLEX FORMATION; DEGENERATIVE DISEASE; DIMERIZATION; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; EPM2A GENE; GENE; GENE EXPRESSION; GENE THERAPY; GENETIC CONSERVATION; GLYCOGEN ANALYSIS; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; LYSOSOME; MOLECULAR MECHANICS; MYOCLONUS EPILEPSY; NERVE CELL LESION; NONHUMAN; PATHOPHYSIOLOGY; PHYLOGENY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN PURIFICATION; PROTEIN UNFOLDING; SYMPTOMATOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; DUAL-SPECIFICITY PHOSPHATASES; GLUCANS; GLYCOGEN; HUMANS; LAFORA DISEASE; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR;

MUS MUSCULUS;

EID: 84872791269     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08549.x     Document Type: Article

References (88)

1. Delgado-Escueta AV, (2007) Advances in lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep 7, 428-433.
2. Gentry MS, Dixon JE, &, Worby CA, (2009) Lafora disease: insights into neurodegeneration from plant metabolism. Trends Biochem Sci 34, 628-639.
3. Ganesh S, Puri R, Singh S, Mittal S, &, Dubey D, (2006) Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J Hum Genet 51, 1-8.
4. Lafora GR, &, Glueck B, (1911) Beitrag zur histogpathologie der myoklonischen epilepsie. Gesamte Neurol Psychiatr 6, 1-14.
5. Collins GH, Cowden RR, &, Nevis AH, (1968) Myoclonus epilepsy with Lafora bodies. An ultrastructural and cytochemical study. Arch Pathol 86, 239-254.
6. Yokoi S, Austin J, Witmer F, &, Sakai M, (1968) Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases. Arch Neurol 19, 15-33.
7. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R, Fong CY, Carpenter S, et al. (1998) Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 20, 171-174.
8. Serratosa JM, Gomez-Garre P, Gallardo ME, Anta B, de Bernabe DB, Lindhout D, Augustijn PB, Tassinari CA, Malafosse RM, Topcu M, et al. (1999) A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 8, 345-352.
9. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, et al. (2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35, 125-127.
10. Chan EM, Omer S, Ahmed M, Bridges LR, Bennett C, Scherer SW, &, Minassian BA, (2004) Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 63, 565-567.
11. Lohi H, Ianzano L, Zhao XC, Chan EM, Turnbull J, Scherer SW, Ackerley CA, &, Minassian BA, (2005) Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum Mol Genet 14, 2727-2736.
12. Gentry MS, Worby CA, &, Dixon JE, (2005) Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci USA 102, 8501-8506.
13. Ganesh S, Agarwala KL, Amano K, Suzuki T, Delgado-Escueta AV, &, Yamakawa K, (2001) Regional and developmental expression of Epm2a gene and its evolutionary conservation. Biochem Biophys Res Commun 283, 1046-1053.
14. Singh S, &, Ganesh S, (2009) Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat 30, 715-723.
15. Dubey D, &, Ganesh S, (2008) Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum Mol Genet 17, 3010-3020.
16. Dubey D, Parihar R, &, Ganesh S, (2012) Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy. Genomics 99, 36-43.
17. Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, &, Henrissat B, (2009) The Carbohydrate-Active EnZymes database (CAZy): an expert resource for Glycogenomics. Nucleic Acids Res 37, D233-D238.
18. Boraston AB, Bolam DN, Gilbert HJ, &, Davies GJ, (2004) Carbohydrate-binding modules: fine-tuning polysaccharide recognition. Biochem J 382, 769-781.
19. Wang J, Stuckey JA, Wishart MJ, &, Dixon JE, (2002) A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J Biol Chem 277, 2377-2380.
20. Janecek S, &, Sevcik J, (1999) The evolution of starch-binding domain. FEBS Lett 456, 119-125.
21. Janecek S, Svensson B, &, Macgregor EA, (2011) Structural and evolutionary aspects of two families of non-catalytic domains present in starch and glycogen binding proteins from microbes, plants and animals. Enzyme Microb Technol 49, 429-440.
22. Machovic M, Svensson B, MacGregor EA, &, Janecek S, (2005) A new clan of CBM families based on bioinformatics of starch-binding domains from families CBM20 and CBM21. FEBS J 272, 5497-5513.
23. Gentry MS, Dowen RH III, Worby CA, Mattoo S, Ecker JR, &, Dixon JE, (2007) The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease. J Cell Biol 178, 477-488.
24. Ganesh S, Tsurutani N, Suzuki T, Hoshii Y, Ishihara T, Delgado-Escueta AV, &, Yamakawa K, (2004) The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem Biophys Res Commun 313, 1101-1109.
25. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, &, Mustelin T, (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699-711.
26. Tonks NK, (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev 7, 833-846.
27. Roma-Mateo C, Solaz-Fuster MC, Gimeno-Alcaniz JV, Dukhande V, Donderis J, Worby CA, Marina A, Criado O, Koller A, Rodriguez de Cordoba S, et al. (2011) Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase. Biochem J 439, 265-275.
28. Machovic M, &, Janecek S, (2006) Starch-binding domains in the post-genome era. Cell Mol Life Sci 63, 2710-2724.
29. Moorhead GB, De Wever V, Templeton G, &, Kerk D, (2009) Evolution of protein phosphatases in plants and animals. Biochem J 417, 401-409.
30. Ganesh S, Agarwala KL, Ueda K, Akagi T, Shoda K, Usui T, Hashikawa T, Osada H, Delgado-Escueta AV, &, Yamakawa K, (2000) Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet 9, 2251-2261.
31. Wang W, &, Roach PJ, (2004) Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase. Biochem Biophys Res Commun 325, 726-730.
32. Girard JM, Le KH, &, Lederer F, (2006) Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease. Biochimie 88, 1961-1971.
33. Dukhande VV, Rogers DM, Roma-Mateo C, Donderis J, Marina A, Taylor AO, Sanz P, &, Gentry MS, (2011) Laforin, a dual specificity phosphatase involved in lafora disease, is present mainly as monomeric form with full phosphatase activity. PLoS ONE 6, e24040.
34. Worby CA, Gentry MS, &, Dixon JE, (2006) Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates. J Biol Chem 281, 30412-30418.
35. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, Delgado-Escueta AV, Minassian BA, Depaoli-Roach AA, &, Roach PJ, (2007) Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA 104, 19262-19266.
36. Yokota T, Nara Y, Kashima A, Matsubara K, Misawa S, Kato R, &, Sugio S, (2007) Crystal structure of human dual specificity phosphatase, JNK stimulatory phosphatase-1, at 1.5 A resolution. Proteins 66, 272-278.
37. Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, &, Moller NP, (2001) Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 21, 7117-7136.
38. Fernandez-Sanchez ME, Criado-Garcia O, Heath KE, Garcia-Fojeda B, Medrano-Fernandez I, Gomez-Garre P, Sanz P, Serratosa JM, &, Rodriguez de Cordoba S, (2003) Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet 12, 3161-3171.
39. Liu Y, Wang Y, Wu C, Liu Y, &, Zheng P, (2006) Dimerization of laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling. J Biol Chem 281, 34768-34774.
40. Castanheira P, Moreira S, Gama M, &, Faro C, (2010) Escherichia coli expression, refolding and characterization of human laforin. Protein Expr Purif 71, 195-199.
41. Gentry MS, &, Pace RM, (2009) Conservation of the glucan phosphatase laforin is linked to rates of molecular evolution and the glucan metabolism of the organism. BMC Evol Biol 9, 138.
42. Roma-Mateo C, Moreno D, Vernia S, Rubio T, Bridges TM, Gentry MS, &, Sanz P, (2011) Lafora disease E3-ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level. BMC Evol Biol 11, 225.
43. Sakai M, Austin J, Witmer F, &, Trueb L, (1970) Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20, 160-176.
44. Kerk D, Conley TR, Rodriguez FA, Tran HT, Nimick M, Muench DG, &, Moorhead GB, (2006) A chloroplast-localized dual-specificity protein phosphatase in Arabidopsis contains a phylogenetically dispersed and ancient carbohydrate-binding domain, which binds the polysaccharide starch. Plant J 46, 400-413.
45. Niittyla T, Comparot-Moss S, Lue WL, Messerli G, Trevisan M, Seymour MD, Gatehouse JA, Villadsen D, Smith SM, Chen J, et al. (2006) Similar protein phosphatases control starch metabolism in plants and glycogen metabolism in mammals. J Biol Chem 281, 11815-11818.
46. Ritte G, Lloyd JR, Eckermann N, Rottmann A, Kossmann J, &, Steup M, (2002) The starch-related R1 protein is an alpha-glucan, water dikinase. Proc Natl Acad Sci USA 99, 7166-7171.
47. Ritte G, Heydenreich M, Mahlow S, Haebel S, Kotting O, &, Steup M, (2006) Phosphorylation of C6- and C3-positions of glucosyl residues in starch is catalysed by distinct dikinases. FEBS Lett 580, 4872-4876.
48. Kotting O, Pusch K, Tiessen A, Geigenberger P, Steup M, &, Ritte G, (2005) Identification of a novel enzyme required for starch metabolism in Arabidopsis leaves. The phosphoglucan, water dikinase. Plant Physiol 137, 242-252.
49. Baunsgaard L, Lutken H, Mikkelsen R, Glaring MA, Pham TT, &, Blennow A, (2005) A novel isoform of glucan, water dikinase phosphorylates pre-phosphorylated alpha-glucans and is involved in starch degradation in Arabidopsis. Plant J 41, 595-605.
50. Fontana JD, (1980) The presence of phosphate in glycogen. FEBS Lett 109, 85-92.
51. Lomako J, Lomako WM, Whelan WJ, &, Marchase RB, (1993) Glycogen contains phosphodiester groups that can be introduced by UDPglucose: glycogen glucose 1-phosphotransferase. FEBS Lett 329, 263-267.
52. Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, Zhao X, Minassian BA, Depaoli-Roach AA, &, Roach PJ, (2008) Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J Biol Chem 283, 33816-33825.
53. Tagliabracci VS, Heiss C, Karthik C, Contreras CJ, Glushka J, Ishihara M, Azadi P, Hurley TD, DePaoli-Roach AA, &, Roach PJ, (2011) Phosphate incorporation during glycogen synthesis and Lafora disease. Cell Metab 13, 274-282.
54. Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, Garcia-Fojeda B, Criado-Garcia O, Fernandez-Sanchez E, Medrano-Fernandez I, Dominguez J, et al. (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10, 1407-1413.
55. Solaz-Fuster MC, Gimeno-Alcaniz JV, Ros S, Fernandez-Sanchez ME, Garcia-Fojeda B, Criado Garcia O, Vilchez D, Dominguez J, Garcia-Rocha M, Sanchez-Piris M, et al. (2008) Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum Mol Genet 17, 667-678.
56. Worby CA, Gentry MS, &, Dixon JE, (2008) Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem 283, 4069-4076.
57. Cheng A, Zhang M, Gentry MS, Worby CA, Dixon JE, &, Saltiel AR, (2007) A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev 21, 2399-2409.
58. Sharma J, Rao SN, Shankar SK, Satishchandra P, &, Jana NR, (2011) Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis. Neurobiol Dis 44, 133-141.
59. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, &, Roach PJ, (2010) Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin. J Biol Chem 285, 25372-25381.
60. Turnbull J, Wang P, Girard JM, Ruggieri A, Wang TJ, Draginov AG, Kameka AP, Pencea N, Zhao X, Ackerley CA, et al. (2010) Glycogen hyperphosphorylation underlies lafora body formation. Ann Neurol 68, 925-933.
61. Valles-Ortega J, Duran J, Garcia-Rocha M, Bosch C, Saez I, Pujadas L, Serafin A, Canas X, Soriano E, Delgado-Garcia JM, et al. (2011) Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease. EMBO Mol Med 3, 667-681.
62. Deshaies RJ, &, Joazeiro CA, (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78, 399-434.
63. Ikeda F, &, Dikic I, (2008) Atypical ubiquitin chains: new molecular signals. EMBO Rep 9, 536-542.
64. Moreno D, Towler MC, Hardie DG, Knecht E, &, Sanz P, (2010) The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits. Mol Biol Cell 21, 2578-2588.
65. Lim KL, Chew KC, Tan JM, Wang C, Chung KK, Zhang Y, Tanaka Y, Smith W, Engelender S, Ross CA, et al. (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 25, 2002-2009.
66. Vernia S, Solaz-Fuster MC, Gimeno-Alcaniz JV, Rubio T, Garcia-Haro L, Foretz M, de Cordoba SR, &, Sanz P, (2009) AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex. J Biol Chem 284, 8247-8255.
67. Vernia S, Rubio T, Heredia M, Rodriguez de Cordoba S, &, Sanz P, (2009) Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PLoS ONE 4, e5907.
68. Rao SN, Maity R, Sharma J, Dey P, Shankar SK, Satishchandra P, &, Jana NR, (2010) Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin. Hum Mol Genet 19, 4726-4734.
69. Mittal S, Dubey D, Yamakawa K, &, Ganesh S, (2007) Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet 16, 753-762.
70. Liu Y, Wang Y, Wu C, Liu Y, &, Zheng P, (2009) Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress. Hum Mol Genet 18, 2622-2631.
71. Garyali P, Siwach P, Singh PK, Puri R, Mittal S, Sengupta S, Parihar R, &, Ganesh S, (2009) The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum Mol Genet 18, 688-700.
72. Rao SN, Sharma J, Maity R, &, Jana NR, (2010) Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease. J Biol Chem 285, 1404-1413.
73. Sengupta S, Badhwar I, Upadhyay M, Singh S, &, Ganesh S, (2011) Malin and laforin are essential components of a protein complex that protects cells from thermal stress. J Cell Sci 124, 2277-2286.
74. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, Sanz P, de Cordoba SR, Knecht E, &, Rubinsztein DC, (2010) Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Hum Mol Genet 19, 2867-2876.
75. Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millan B, Heredia M, Roma-Mateo C, Mouron S, et al. (2012) Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Hum Mol Genet in press, PMID22186026.
76. Geiger T, Gooding LR, &, Flavell RA, (1992) T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci USA 89, 2985-2989.
77. Wang Y, Liu Y, Wu C, Zhang H, Zheng X, Zheng Z, Geiger TL, Nuovo GJ, Liu Y, &, Zheng P, (2006) Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell 10, 179-190.
78. Liu R, Wang L, Chen C, Liu Y, Zhou P, Wang Y, Wang X, Turnbull J, Minassian BA, Liu Y, et al. (2008) Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3beta-dependent mechanisms. Mol Cell Biol 28, 7236-7244.
79. Wang W, Lohi H, Skurat AV, DePaoli-Roach AA, Minassian BA, &, Roach PJ, (2007) Glycogen metabolism in tissues from a mouse model of Lafora disease. Arch Biochem Biophys 457, 264-269.
80. Wang W, Parker GE, Skurat AV, Raben N, DePaoli-Roach AA, &, Roach PJ, (2006) Relationship between glycogen accumulation and the laforin dual specificity phosphatase. Biochem Biophys Res Commun 350, 588-592.
81. Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, Piliguian M, Roach PJ, Wang P, Ackerley CA, et al. (2011) PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet 7, e1002037.
82. Pardridge WM, (2010) Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb Protoc 2010, pdb prot5407.
83. Howard M, Frizzell RA, &, Bedwell DM, (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2, 467-469.
84. Delgado-Escueta AV, &, Bourgeois BF, (2008) Debate: does genetic information in humans help us treat patients? PRO-genetic information in humans helps us treat patients. CON-genetic information does not help at all. Epilepsia 49, 13-24.
85. Ganesh S, Tsurutani N, Suzuki T, Ueda K, Agarwala KL, Osada H, Delgado-Escueta AV, &, Yamakawa K, (2003) The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain. Hum Mol Genet 12, 2359-2368.
86. Ianzano L, Zhao XC, Minassian BA, &, Scherer SW, (2003) Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product. Genomics 81, 579-587.
87. Puri R, Suzuki T, Yamakawa K, &, Ganesh S, (2009) Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease. J Biol Chem 284, 22657-22663.
88. Cavalier-Smith T, (2004) Only six kingdoms of life. Proc Biol Sci 271, 1251-1262.